Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2014
14 août 2013 16h29 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Announces Fiscal Year 2014 First Quarter Conference Call on Thursday, August 15, 2013
13 août 2013 11h59 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals, Inc. Appoints Nasrat Hakim as President and Chief Executive Officer
05 août 2013 07h00 HE
|
Elite Pharmaceuticals, Inc.
Elite Adds Twelve Approved Products to Its Pipeline
Conference Call Scheduled for 1 PM Eastern Time
NORTHVALE, N.J., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP)...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corporate History
21 juin 2013 13h44 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 21, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
TAGI Pharma Announces Exclusive Marketing Rights Agreement for Alendronate Sodium Oral Solution, 70mg/75ml x 4 Pack Unit of Use
30 avr. 2013 11h22 HE
|
TAGI Pharma, Inc.
SOUTH BELOIT, Ill., April 30, 2013 (GLOBE NEWSWIRE) -- TAGI Pharma, Inc., a specialty pharmaceutical company and subsidiary of Precision Dose, Inc., announced today the signing of an exclusive...
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation
23 avr. 2013 08h23 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled...
Elite Pharmaceuticals, Inc. Secures $10 Million Funding Commitment From Lincoln Park Capital Fund, LLC
22 avr. 2013 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that it has entered into a $10 million common stock purchase...
Elite Pharmaceuticals, Inc. Announces First Shipment of Generic Phentermine Capsules
11 avr. 2013 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of phentermine HCl capsules 15 mg and 30 mg...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal 2013
14 févr. 2013 16h20 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release...
Elite Pharmaceuticals, Inc. to Discuss Third Quarter Results of Operations on Monday, February 14, 2011
10 févr. 2011 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...